Index S&P 500 P/E - EPS (ttm) -2.96 Insider Own 2.05% Shs Outstand 1.15B Perf Week -5.02%
Market Cap 15.89B Forward P/E 5.18 EPS next Y 2.66 Insider Trans 0.00% Shs Float 1.13B Perf Month -13.48%
Enterprise Value 29.14B PEG 0.34 EPS next Q 0.51 Inst Own 84.52% Short Float 2.51% Perf Quarter 23.32%
Income -3.51B P/S 1.11 EPS this Y 4.69% Inst Trans 0.41% Short Ratio 2.77 Perf Half Y 34.77%
Sales 14.29B P/B 1.08 EPS next Y 8.29% ROA -8.93% Short Interest 28.26M Perf YTD 10.84%
Book/sh 12.78 P/C 10.92 EPS next 5Y 15.02% ROE -21.08% 52W High 16.47 -16.21% Perf Year 49.35%
Cash/sh 1.26 P/FCF 8.20 EPS past 3/5Y - -21.93% ROIC -12.84% 52W Low 6.85 101.46% Perf 3Y 38.00%
Dividend Est. 0.52 (3.76%) EV/EBITDA 7.39 Sales past 3/5Y -4.04% 3.66%Gross Margin 38.49% Volatility 2.90% 3.17% Perf 5Y -3.90%
Dividend TTM 0.48 (3.48%) EV/Sales 2.04 EPS Y/Y TTM -456.43% Oper. Margin 7.99% ATR (14) 0.49 Perf 10Y -71.60%
Dividend Ex-Date Mar 09, 2026 Quick Ratio 0.74 Sales Y/Y TTM -2.61% Profit Margin -24.59% RSI (14) 37.81 Recom 2.42
Dividend Gr. 3/5Y 0.00% - Current Ratio 1.30 EPS Q/Q 31.80% SMA20 -9.09% Beta 0.81 Target Price 15.62
Payout - Debt/Eq 1.00 Sales Q/Q 6.60% SMA50 -2.04% Rel Volume 1.33 Prev Close 13.97
Employees 30000 LT Debt/Eq 0.86 Earnings Feb 26 BMO SMA200 25.18% Avg Volume 10.22M Price 13.80
IPO Mar 17, 1980 Option/Short Yes / Yes EPS/Sales Surpr. 7.08% 4.85% Trades
Volume 13,426,732 Change -1.22%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-09-26 Upgrade UBS
Neutral → Buy
$18
Jan-16-26 Upgrade Argus
Hold → Buy
$15
Dec-09-25 Initiated Barclays
Overweight
$15
Oct-15-25 Initiated Truist
Buy
$15
Jun-06-25 Initiated Goldman
Neutral
$10
Jul-19-24 Resumed Jefferies
Buy
$15
Oct-23-23 Downgrade BofA Securities
Neutral → Underperform
$13 → $9
Jun-23-23 Downgrade Barclays
Equal Weight → Underweight
$11
Apr-24-23 Downgrade Barclays
Overweight → Equal Weight
$11
Feb-17-23 Downgrade BMO Capital Markets
Outperform → Market Perform
$16 → $14
Jan-27-23 Upgrade Jefferies
Hold → Buy
$13 → $15
Nov-10-22 Upgrade UBS
Sell → Neutral
$9 → $12
Nov-08-22 Upgrade Piper Sandler
Underweight → Neutral
$10
Oct-21-22 Resumed Jefferies
Hold
$11
Jun-14-22 Initiated UBS
Sell
$9
May-10-22 Downgrade Piper Sandler
Neutral → Underweight
$10
Mar-01-22 Downgrade Raymond James
Outperform → Mkt Perform
Mar-01-22 Downgrade BofA Securities
Buy → Neutral
$21 → $13
Jun-15-21 Initiated Citigroup
Neutral
$16
Apr-07-21 Resumed RBC Capital Mkts
Outperform
$24
Show Previous Ratings
Mar-10-26 12:02AM
Mar-04-26 09:40AM
Mar-03-26 05:25AM
Mar-02-26 10:34PM
Feb-28-26 12:40PM
07:02AM
Loading…
Feb-27-26 07:02AM
Feb-26-26 04:08PM
02:24PM
11:44AM
10:00AM
09:55AM
08:37AM
07:27AM
07:10AM
(Associated Press Finance)
06:59AM
06:55AM
Loading…
06:55AM
Feb-25-26 06:59AM
Feb-24-26 10:24PM
08:02AM
Feb-23-26 09:15AM
09:07AM
09:06AM
Feb-19-26 10:00AM
Feb-18-26 03:54AM
Feb-10-26 06:41AM
Feb-09-26 04:34PM
03:31PM
Feb-06-26 07:00PM
(The Wall Street Journal)
Feb-03-26 04:34PM
08:30AM
08:42AM
Loading…
Feb-02-26 08:42AM
Jan-22-26 06:33AM
Jan-21-26 11:02PM
Jan-20-26 06:59AM
Jan-08-26 09:05AM
Jan-06-26 12:00PM
Jan-02-26 09:44AM
Dec-30-25 05:38PM
Dec-19-25 12:17PM
Dec-18-25 06:59AM
Dec-17-25 06:59AM
Dec-15-25 10:33AM
Dec-08-25 05:17AM
(Pharmaceutical Business Review)
Dec-06-25 09:00AM
Dec-04-25 02:08PM
Nov-24-25 08:00AM
Nov-19-25 03:00AM
Nov-14-25 08:44AM
Nov-13-25 08:00AM
Nov-12-25 10:36PM
07:00AM
Nov-11-25 07:47PM
(Morningstar Research) +10.13%
03:55PM
10:10AM
Nov-06-25 03:33PM
(Morningstar Research) -5.95%
10:24AM
09:30AM
08:15AM
07:22AM
07:10AM
(Associated Press Finance)
06:59AM
Nov-05-25 09:15AM
08:10AM
Nov-04-25 10:13PM
07:09AM
06:59AM
Nov-02-25 11:34PM
Oct-30-25 02:05PM
10:00AM
Oct-28-25 09:40AM
Oct-24-25 08:42AM
08:07AM
Oct-22-25 12:04AM
Oct-21-25 12:10PM
05:52AM
Oct-16-25 11:14AM
Oct-15-25 04:30PM
Oct-13-25 06:59AM
Oct-09-25 05:10AM
(The Wall Street Journal)
Oct-08-25 11:00AM
Oct-01-25 09:00AM
Sep-26-25 08:57AM
Sep-23-25 07:10PM
Sep-16-25 09:31AM
Sep-04-25 03:45AM
Sep-03-25 11:30AM
Sep-02-25 12:57PM
Aug-29-25 05:03AM
Aug-19-25 11:34PM
09:00AM
Aug-14-25 01:34AM
Aug-13-25 12:23AM
Aug-12-25 06:32AM
(Pharmaceutical Business Review)
Aug-11-25 12:31PM
09:29AM
Aug-08-25 01:10PM
(Pharmaceutical Technology)
Aug-07-25 05:43PM
(Morningstar Research) +7.31%
02:39PM
11:00AM
09:30AM
Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. It provides medicines and treatments in various therapeutic areas such as cardiovascular, oncology, dermatology, eye care, gastroenterology, immunology, and women's healthcare. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan, and Hong Kong. The JANZ segment covers operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses operations in developing markets and emerging economies including in Asia, the Middle East, South and Central America, Africa, and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Le Goff Corinne Chief Commercial Officer Mar 06 '26 Option Exercise 0.00 46,358 0 101,582 Mar 10 07:04 PM Mistras Theodora Chief Financial Officer Mar 06 '26 Option Exercise 0.00 43,782 0 92,787 Mar 10 07:04 PM SEVERINO MICHAEL Director Mar 06 '26 Option Exercise 0.00 26,031 0 26,031 Mar 10 07:03 PM PARRISH MARK W Director Mar 06 '26 Option Exercise 0.00 24,835 0 165,230 Mar 10 07:03 PM MARK RICHARD A Director Mar 06 '26 Option Exercise 0.00 24,835 0 116,145 Mar 10 07:03 PM Campbell Paul See Remarks Mar 06 '26 Option Exercise 0.00 28,974 0 398,956 Mar 10 07:03 PM Smith Scott Andrew Chief Executive Officer Mar 06 '26 Option Exercise 0.00 130,701 0 1,374,576 Mar 10 07:03 PM HIGGINS MELINA E Director Mar 06 '26 Option Exercise 0.00 24,835 0 146,048 Mar 10 07:03 PM Groothuis Leo Frans Director Mar 06 '26 Option Exercise 0.00 24,835 0 63,567 Mar 10 07:03 PM SIMMONS DAVID S Director Mar 06 '26 Option Exercise 0.00 23,344 0 23,344 Mar 10 07:03 PM SIMMONS DAVID S Director Aug 27 '25 Buy 10.42 286 2,981 970 Mar 10 07:03 PM SIMMONS DAVID S Director Nov 03 '25 Buy 10.43 213 2,221 1,183 Mar 10 07:03 PM Lyons Dillon JoEllen Director Mar 06 '26 Option Exercise 0.00 24,835 0 102,526 Mar 10 07:03 PM KILTS JAMES M Director Mar 06 '26 Option Exercise 0.00 24,835 0 161,257 Mar 10 07:03 PM Vivaldi Coelho Rogerio Director Mar 06 '26 Option Exercise 0.00 24,835 0 46,526 Mar 10 07:03 PM DAMELIO FRANK A Director Mar 06 '26 Option Exercise 0.00 26,031 0 26,031 Mar 10 07:03 PM CORNWELL W DON Director Mar 06 '26 Option Exercise 0.00 24,835 0 112,044 Mar 10 07:03 PM FINNEY ELISHA W Director Mar 06 '26 Option Exercise 0.00 24,835 0 62,667 Mar 10 07:03 PM Mistras Theodora Chief Financial Officer Mar 04 '26 Option Exercise 0.00 34,084 0 66,991 Mar 05 07:00 PM Le Goff Corinne Chief Commercial Officer Mar 04 '26 Option Exercise 0.00 39,773 0 72,019 Mar 05 07:00 PM Enrietti Andrew See Remarks Mar 03 '26 Option Exercise 0.00 110,630 0 248,032 Mar 05 07:00 PM Campbell Paul See Remarks Mar 04 '26 Option Exercise 0.00 18,720 0 377,939 Mar 05 07:00 PM Campbell Paul See Remarks Mar 03 '26 Option Exercise 0.00 190,027 0 435,151 Mar 05 07:00 PM Smith Scott Andrew Chief Executive Officer Mar 04 '26 Option Exercise 0.00 101,217 0 1,281,172 Mar 05 07:00 PM Smith Scott Andrew Chief Executive Officer Mar 03 '26 Option Exercise 0.00 1,440,831 0 1,695,045 Mar 05 07:00 PM Mistras Theodora Chief Financial Officer Jan 01 '26 Option Exercise 0.00 25,260 0 48,265 Jan 02 06:00 PM Le Goff Corinne Chief Commercial Officer Sep 11 '25 Sale 10.25 7,032 72,045 35,299 Sep 12 06:00 PM Le Goff Corinne Officer Sep 11 '25 Proposed Sale 10.25 7,032 72,045 Sep 11 08:05 PM Smith Scott Andrew Chief Executive Officer Aug 12 '25 Buy 9.99 22,000 219,740 314,807 Aug 13 06:08 PM Smith Scott Andrew Chief Executive Officer May 12 '25 Buy 8.94 60,000 536,262 292,807 May 14 06:00 PM Le Goff Corinne Chief Commercial Officer Apr 15 '25 Option Exercise 0.00 41,112 0 60,441 Apr 16 06:00 PM
